Although the UK’s new R&D tax relief regime came into force on 1 April 2024, many companies have only now completed their first...

At the start of the year, our editors (Xisca Borrás, Katie Cambrook and Aida Tohala) presented to you the 12th edition of our Biotech...

Earlier this month, Ellen Lambrix and Luca Cericola from Bristows’ Commercial & IP Transactions team attended the Licensing Executives...

We explore the complexities of navigating share option plans on both sides of the Atlantic. For companies looking to reward employees...

On 18 March 2025, Bristows attended the Wired Health 2025 conference, which took place at Kings Place in London. It was a day gathering...

In 2024 biotech venture funding in Europe and the US saw a promising increase, reaching a total of $28.1 billion up from $21.2 billion...

This article is part of our Biotech Review of the Year - Issue 12 publication. We help biotech companies to navigate the developing...

This article is part of our Biotech Review of the Year - Issue 12 publication. Following the success of Covid-19 vaccines, the mRNA...

This article is part of our Biotech Review of the Year - Issue 12 publication. It is now over a quarter of a century since the first...

This article is part of our Biotech Review of the Year - Issue 12 publication. On 19 December 2024, the CJEU handed down its decision in...

This article is part of our Biotech Review of the Year - Issue 12 publication. Introduction Denigration – false or misleading statements...

This article is part of our Biotech Review of the Year - Issue 12 publication. The National Security and Investment Act 2021 (NSIA)...